Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2016-08-17 07:39:08
Reporting Period:
Filing Date:
Accepted Time:
2016-08-17 07:39:08
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1369868 China Biologic Products Inc. CBPO Biological Products, (No Disgnostic Substances) (2836) 752308816
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1584733 Cbpo Gang Yang 18Th Floor, Jialong I Nternational
Building, 19 Chaoyang Park Road
Beijing F4 100125
Corporate Vice President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-08-15 8,400 $124.32 32,242 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
  1. Represents 8,400 shares of common stock (the "Sold Common Stock") sold on the open market at a weighted average price of $124.32 per share on August 15, 2016. The Reporting Person intends to use a portion of the proceeds from the sales of the Sold Common Stock to pay income tax due in connection with the scheduled vesting of certain restricted stock held by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from $124.00 to $125.13, inclusive. The Reporting Person undertakes to provide to any security holders of the Issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Footnote 2.